TW202333773A - Glp-1受體和gip受體雙重激動劑的醫藥組成物及其用途 - Google Patents

Glp-1受體和gip受體雙重激動劑的醫藥組成物及其用途 Download PDF

Info

Publication number
TW202333773A
TW202333773A TW111143259A TW111143259A TW202333773A TW 202333773 A TW202333773 A TW 202333773A TW 111143259 A TW111143259 A TW 111143259A TW 111143259 A TW111143259 A TW 111143259A TW 202333773 A TW202333773 A TW 202333773A
Authority
TW
Taiwan
Prior art keywords
pharmaceutical composition
ala
pharmaceutically acceptable
sodium
acceptable salt
Prior art date
Application number
TW111143259A
Other languages
English (en)
Chinese (zh)
Inventor
李振斌
陳菁
曹雪騰
劉凱
Original Assignee
大陸商福建盛迪醫藥有限公司
大陸商江蘇恆瑞醫藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商福建盛迪醫藥有限公司, 大陸商江蘇恆瑞醫藥股份有限公司 filed Critical 大陸商福建盛迪醫藥有限公司
Publication of TW202333773A publication Critical patent/TW202333773A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
TW111143259A 2021-11-12 2022-11-11 Glp-1受體和gip受體雙重激動劑的醫藥組成物及其用途 TW202333773A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111341752 2021-11-12
CN202111341752.0 2021-11-12

Publications (1)

Publication Number Publication Date
TW202333773A true TW202333773A (zh) 2023-09-01

Family

ID=86335124

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111143259A TW202333773A (zh) 2021-11-12 2022-11-11 Glp-1受體和gip受體雙重激動劑的醫藥組成物及其用途

Country Status (10)

Country Link
US (1) US20250115654A1 (cg-RX-API-DMAC7.html)
EP (1) EP4431522A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024546026A (cg-RX-API-DMAC7.html)
KR (1) KR20240109258A (cg-RX-API-DMAC7.html)
CN (1) CN118103391A (cg-RX-API-DMAC7.html)
AU (1) AU2022386489A1 (cg-RX-API-DMAC7.html)
CA (1) CA3237796A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024005663A (cg-RX-API-DMAC7.html)
TW (1) TW202333773A (cg-RX-API-DMAC7.html)
WO (1) WO2023083301A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116693652B (zh) * 2023-08-02 2024-01-05 北京惠之衡生物科技有限公司 一种glp-1/gip受体双重激动剂衍生物及其制备方法和应用
WO2025124473A1 (zh) 2023-12-12 2025-06-19 江苏恒瑞医药股份有限公司 Glp-1类似物治疗代谢疾病的方法及医药用途
WO2025149039A1 (zh) * 2024-01-12 2025-07-17 杭州中美华东制药有限公司 长效glp-1/gip双激动剂的药物组合物
WO2025252197A1 (zh) * 2024-06-07 2025-12-11 江苏恒瑞医药股份有限公司 药物组合物
TW202611066A (zh) * 2024-08-16 2026-03-16 大陸商江蘇恆瑞醫藥股份有限公司 Glp-1類似物的醫藥用途
WO2026092429A1 (zh) * 2024-10-28 2026-05-07 江苏恒瑞医药股份有限公司 药物递送组合物
WO2026153399A1 (zh) * 2025-01-15 2026-07-23 江苏恒瑞医药股份有限公司 一种药物组合物
WO2026153411A1 (zh) * 2025-01-20 2026-07-23 江苏豪森药业集团有限公司 一种双重激动剂的药物组合物、制备方法及其医药用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101987868B (zh) * 2009-07-30 2013-09-04 江苏豪森医药集团有限公司 Glp-1类似物的衍生物或其可药用盐和用途
RU2013133803A (ru) * 2010-12-22 2015-01-27 Маркадиа Байотек, Инк. Способы лечения метаболических нарушений и ожирения при помощи пептидов на основе глюкагона, активных по отношению к рецепторам гип и гпп
KR102002783B1 (ko) * 2011-06-10 2019-07-24 베이징 한미 파마슈티컬 컴퍼니 리미티드 포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용
CA2872314C (en) * 2012-05-03 2021-08-31 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
HUE035803T2 (en) * 2012-12-21 2018-05-28 Sanofi Sa Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
JP7250706B2 (ja) * 2017-06-21 2023-04-03 アムジエン・インコーポレーテツド 胃抑制ペプチド受容体(gipr)に対するアンタゴニスト結合タンパク質/glp-1受容体アゴニスト融合タンパク質を使用した代謝障害の治療又は寛解方法
MY206306A (en) * 2018-10-26 2024-12-07 Novo Nordisk As Stable semaglutide compositions and uses thereof
AU2020256648B2 (en) * 2019-04-11 2026-01-15 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Multi-receptor agonist and medical use thereof
WO2021053578A1 (en) * 2019-09-19 2021-03-25 Dr. Reddy’S Laboratories Limited Improved purification processes for liraglutide
AU2020418207A1 (en) * 2019-12-30 2022-08-25 Gan & Lee Pharmaceuticals Co., Ltd. Long-acting GLP-1 compound
CN118754965A (zh) * 2020-05-29 2024-10-11 北京拓界生物医药科技有限公司 Glp-1和gip受体双重激动剂化合物及其应用

Also Published As

Publication number Publication date
CN118103391A (zh) 2024-05-28
JP2024546026A (ja) 2024-12-17
AU2022386489A1 (en) 2024-05-23
MX2024005663A (es) 2024-05-28
KR20240109258A (ko) 2024-07-10
WO2023083301A1 (zh) 2023-05-19
EP4431522A1 (en) 2024-09-18
CA3237796A1 (en) 2023-05-19
EP4431522A4 (en) 2025-03-26
US20250115654A1 (en) 2025-04-10

Similar Documents

Publication Publication Date Title
US20250115654A1 (en) Pharmaceutical composition of glp-1 receptor and gip receptor dual agonist, and use thereof
TWI924637B (zh) 一種多受體激動劑及其醫藥組成物和用途
TWI910174B (zh) Glp-1和gip受體雙重激動劑化合物及其應用
US8501693B2 (en) Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen
KR101772372B1 (ko) Glp-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
WO2021136302A1 (zh) 胰岛素衍生物
US20260014232A1 (en) Pharmaceutical Composition of GLP-1 and GIP Receptor Dual Agonist and Use Thereof
US20090209469A1 (en) Use of Exendins and GLP-1 Receptor Agonists for Altering Lipoprotein Particle Size and Subclass Composition
CN113383014A (zh) 双受体重激动剂化合物及其药物组合物
TW202502808A (zh) Glp-1、gip和gcg受體三激動劑及其應用
CN115279341B (zh) 胰高血糖素类似物的液体制剂
WO2025252197A1 (zh) 药物组合物
EA053272B1 (ru) Фармацевтическая композиция двойного агониста рецептора glp-1 и рецептора gip и ее применение
RU2848325C1 (ru) Соединение с двойной агонистической активностью в отношении рецепторов glp-1 и gip и его применение
US20250154220A1 (en) Insulin analogs for the treatment of human metabolic disorder and disease
HK40069563B (en) Dual-agonist compound for both glp-1 and gip receptors and application thereof
HK40069563A (en) Dual-agonist compound for both glp-1 and gip receptors and application thereof
HK40051504A (en) Dual receptor-acting agonist compounds and pharmaceutical composition thereof
HK40043112A (en) Multi-receptor agonist and medical use thereof